written on 07.03.2014
Tags:
,

Gilead's Sovaldi sales through the roof already, analyst predicts at least $8B this year

TAGS: ,

With a revolutionary approach to hepatitis C and a price tag of $84,000 per 12-week treatment course, analysts expected big sales from Gilead's Sovaldi. Some even forecast it would reach $9 billion or more by 2017, at which level it would surpass Pfizer's Lipitor to take the crown for biggest-selling drug of all time. But none expected the exponential growth the drug is posting right now.

Latest Report